TMEM16A/ANO1 suppression improves response to antibody‐mediated targeted therapy of EGFR and HER2/ERBB2
Sucheta Kulkarni(University of Pittsburgh Medical Center), Umamaheswar Duvvuri(City University of New York), Neal R. Godse(University of Pittsburgh Medical Center), L. Alex Gaither(Pathways Behavioral Services), Douglas E. Holt(University of Colorado Anschutz Medical Campus), Jason Kass(Brigham and Women's Hospital), Carol A. Bertrand(University of Pittsburgh), Avani R. Vyas(University of Pittsburgh Medical Center), Kevin Steehler(University of Pittsburgh Medical Center), Carolyn Kemp(University of Pittsburgh Medical Center), Jennifer R. Grandis(University of California, San Francisco), Nayel Khan(University of Pittsburgh Medical Center), Kara S. Davis(University of Pittsburgh), Anke Bill(Novartis (China))
Cited by 46
Related Papers
Head and neck squamous cell carcinoma
|Nature Reviews Disease Primers|2020|4k
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
|Cancer Discovery|2013|590
Characterization of HPV and host genome interactions in primary head and neck cancers
|Proceedings of the National Academy of Sciences|2014|401